The company is now pivoting toward survival mode, launching a cost-containment strategy and seeking an investment bank to explore paths for maximizing shareholder value. While the primary goal of the trial remained elusive, management noted an exploratory finding of zero deaths among treated patients, compared with one fatality in the control group. Longeveron intends to discuss these results with the Food and Drug Administration to assess whether a viable regulatory path for the syndrome still exists.

Beyond the pediatric heart program, the firm is shifting its focus toward longevity and aging-related frailty. Executives stated they are actively pursuing alternative funding and revenue streams for laromestrocel, aiming to leverage data from separate clinical trials to keep the asset alive despite the significant setback in its primary indication.